Overbought Stocks — Financial View · Pharmaceutical Preparations
30 stocks match the Overbought Stocks screen. Stocks with an RSI (14) above 70 — technically overbought, most-overbought first. Financial columns. Filtered to Pharmaceutical Preparations. Data as of close · Checked
| PCRX | Pacira Biosciences, Inc. | $1.5B | — | 1.2% | 2.2% | 1.4% | 5.04 | 0.54 | 79.2% | 2.7% | 2.0% | 36.42 | +0.10% | 165K |
| VRDN | Viridian Therapeutics, Inc.De | $3.3B | — | -44.1% | -78.1% | -75.4% | 14.46 | 0.04 | — | — | — | 29.05 | +15.62% | 819K |
| RDY | Dr Reddys Laboratories Ltd | — | — | — | — | — | — | — | — | — | — | 14.77 | +3.18% | 248K |
| INM | InMed Pharmaceuticals Inc. | $10M | — | — | — | — | 0.65 | — | — | — | — | 1.80 | +6.82% | 1K |
| LYEL | Lyell Immunopharma, Inc. | $380M | — | -93.2% | — | — | 4.02 | 0.42 | — | — | — | 15.47 | +42.98% | 53K |
| KRRO | Korro Bio, Inc. | $244M | — | -65.2% | — | — | 9.55 | 0.00 | — | — | — | 16.59 | +4.73% | 9K |
| XNCR | Xencor Inc | $2.6B | — | -15.3% | -21.0% | -18.6% | 6.54 | 0.13 | — | -72.7% | -58.8% | 35.03 | +14.33% | 113K |
| SLN | Silence Therapeutics Plc | $2.8B | — | -56.3% | — | — | 7.42 | 1.77 | 85.9% | — | — | 19.79 | +0.00% | 70K |
| LKFT | Lakefront Biotherapeutics Nv | — | — | — | — | — | — | — | — | — | — | 34.10 | +6.07% | 27K |
| ZTS | Zoetis | $36.8B | 1.7% | 17.4% | 83.1% | 21.4% | 3.08 | 2.87 | 71.5% | — | 27.5% | 89.16 | +7.40% | 347K |
| SNY | Sanofi | — | — | — | — | — | — | — | — | — | — | 47.44 | +4.65% | 446K |
| GMAB | Genmab A/S | — | — | — | — | — | — | — | — | — | — | 55.08 | -0.74% | 328K |
| LLY | Lilly (Eli) | $1.33T | 0.5% | 18.6% | 68.5% | 31.6% | 1.39 | 1.17 | 83.6% | — | 31.9% | 1418.07 | +0.62% | 192K |
| GRFS | Grifols Sa | — | — | — | — | — | — | — | — | — | — | 8.60 | +0.53% | 52K |
| DMAC | DiaMedica Therapeutics Inc. | $582M | — | -83.4% | -97.9% | — | 6.72 | — | — | — | — | 10.79 | +7.68% | 30K |
| RPRX | Royalty Pharma Plc | $30.1B | 1.4% | 3.5% | 6.9% | 3.7% | 1.29 | 0.88 | — | 57.1% | 25.7% | 67.56 | +1.82% | 202K |
| ABT | Abbott Laboratories | $200.2B | 2.2% | 4.3% | 9.2% | 5.8% | 1.45 | 0.58 | 56.9% | 13.8% | 9.7% | 115.57 | +5.61% | 933K |
| PHAR | Pharming Group N.V. | — | — | — | — | — | — | — | — | — | — | 12.92 | +0.31% | 29 |
| BBIO | Bridgebio Pharma, Inc. | $15.2B | — | -33.9% | — | — | 2.09 | — | 94.3% | -38.5% | — | 77.97 | +5.36% | 383K |
| AZN | Astrazeneca Plc | — | — | — | — | — | — | — | — | — | — | 189.00 | +2.77% | 352K |
| TRAX | First Tracks Biotherapeutics, Inc. | $2.1B | — | — | — | — | 9.16 | — | — | — | — | 49.13 | +5.93% | 74K |
| SEPN | Septerna, Inc. | $2.2B | — | -4.3% | -6.3% | -6.3% | 4.99 | 0.47 | — | -44.0% | -24.5% | 47.88 | +9.47% | 57K |
| BHC | Bausch Health Companies Inc. | $3.1B | — | -3.3% | — | — | 1.56 | — | — | 11.2% | -7.6% | 8.34 | +2.58% | 253K |
| UTHR | United Therapeutics Corp | $25.9B | — | 17.5% | 19.6% | 19.6% | 4.61 | 0.12 | 86.3% | 41.4% | 38.6% | 607.43 | +0.95% | 68K |
| TAK | Takeda Pharmaceutical Co Ltd | — | — | — | — | — | — | — | — | — | — | 21.07 | +1.47% | 205K |
| ZYME | Zymeworks Inc. | $2.2B | — | -37.8% | — | — | 6.32 | 3.94 | — | -87.3% | -76.6% | 30.94 | +2.69% | 40K |
| ELAN | Elanco Animal Health Inc | $12.6B | — | -1.5% | -3.0% | -1.9% | 2.05 | 0.56 | 55.4% | — | -4.0% | 25.31 | +2.97% | 920K |
| NVS | Novartis Ag | — | — | — | — | — | — | — | — | — | — | 165.02 | +3.64% | 116K |
| ORKA | Oruka Therapeutics, Inc. | $6.7B | — | -11.7% | -11.9% | -11.9% | 38.51 | 0.00 | — | — | — | 101.48 | +1.85% | 40K |
| PVLA | Palvella Therapeutics, Inc. | $2.3B | — | -24.3% | -28.4% | -28.4% | 21.18 | 0.17 | — | — | — | 162.66 | +6.31% | 34K |
Source: SEC EDGAR/XBRL (fundamentals, shares) · Databento EQUS.MINI (EOD prices) · multiples, ratios & technicals computed by tradmap. Financials: Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it. A company reporting in another currency is shown in ≈ USD: its figures convert at the Federal Reserve H.10 rate of its price date (FRED), and without a rate its multiples are blank. This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis. Informational only — not financial advice.